Literature DB >> 27288034

Efficacy and tolerability of ethionamide versus prothionamide: a systematic review.

Anna Scardigli1, Jose A Caminero2, Giovanni Sotgiu3, Rosella Centis4, Lia D'Ambrosio5, Giovanni Battista Migliori6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27288034     DOI： 10.1183/13993003.00438-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  8 in total

1.  Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.

Authors:  Clarisse A Tsang; Neha Shah; Lori R Armstrong; Suzanne M Marks
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

2.  Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis.

Authors:  Mohammad H Al-Shaer; Anne-Grete Märtson; Wael A Alghamdi; Abdullah Alsultan; Guohua An; Shahriar Ahmed; Yosra Alkabab; Sayera Banu; Eric R Houpt; David Ashkin; David E Griffith; J Peter Cegielski; Scott K Heysell; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

3.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

4.  Prothionamide Dose Optimization Using Population Pharmacokinetics for Multidrug-Resistant Tuberculosis Patients.

Authors:  Hwi-Yeol Yun; Min Jung Chang; Heeyoon Jung; Vincent Chang; Qianwen Wang; Natasha Strydom; Young-Ran Yoon; Radojka M Savic
Journal:  Antimicrob Agents Chemother       Date:  2022-08-08       Impact factor: 5.938

5.  Mutation EthAW21R confers co-resistance to prothionamide and ethionamide in both Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rv.

Authors:  Julius Mugweru; Jianxiong Liu; Gaelle Makafe; Gift Chiwala; Bangxing Wang; Changwei Wang; Xinjie Li; Yaoju Tan; Wing Wai Yew; Shouyong Tan; Tianyu Zhang
Journal:  Infect Drug Resist       Date:  2018-06-13       Impact factor: 4.003

Review 6.  MDR Tuberculosis Treatment.

Authors:  Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430

Review 7.  Effectiveness and Safety of Short-term Regimen for Multidrug-resistant Tuberculosis Treatment: A Systematic Review of Cohort Studies.

Authors:  Putu Nandika Mahardani; Dyah Kanya Wati; Azriel Siloam; Ni Putu Ayu Savitri; Arya Krisna Manggala
Journal:  Oman Med J       Date:  2022-01-31

8.  Molecular Determinants of Ethionamide Resistance in Clinical Isolates of Mycobacterium tuberculosis.

Authors:  Anastasia Ushtanit; Elena Kulagina; Yulia Mikhailova; Marina Makarova; Svetlana Safonova; Danila Zimenkov
Journal:  Antibiotics (Basel)       Date:  2022-01-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.